This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.64% per year. These returns cover a period from January 1, 1988 through August 4, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
3 Top Sector ETFs to Start Q3 With More Room for Growth
by Sanghamitra Saha
We entered the third quarter some weeks ago with no abatement (rather surges) on the virus front and several U.S. states reversing the course of economic reopening.
Biotech ETFs to Gain on Coronavirus Vaccine Progress
by Sweta Jaiswal, FRM
The race to find a coronavirus vaccine is heating up as the latest positive data from progress in trials are being published.
The Zacks Analyst Blog Highlights: AstraZeneca, Pfizer, Moderna, Vaxart and Novovax
by Zacks Equity Research
The Zacks Analyst Blog Highlights: AstraZeneca, Pfizer, Moderna, Vaxart and Novovax
EU Stimulus, Vaccine Hopes Aid Oil Price, Upstream Stocks Rise
by Kaibalya Pravo Dey
Significant gains in crude prices are likely to provide a profit-boosting opportunity to exploration and production companies.
3 Small Biotechs in Focus on Promising Coronavirus Vaccine Data
by Zacks Equity Research
Pfizer (PFE) and AstraZeneca (AZN) announce promising data from early-stage coronavirus vaccine studies. Here we discuss three leading biotechs with potential to recshare price gains.
Top and Flop ETFs to Start Third Quarter
by Sweta Killa
We have highlighted ETFs from the best and worst zones to start the third quarter.
Quiet Week Could be the Calm Before the Storm
by David Borun
A busy week of earnings reports and Congressional stimulus talks has t
Vaxart's Soars YTD on Robust Coronavirus Vaccine Progress
by Zacks Equity Research
Vaxart's (VXRT) oral coronavirus vaccine candidate is chosen by Operation Warp Speed for a vaccine study. Last month, the company picked its lead COVID-19 vaccine candidate.
Moderna (MRNA) Gains As Market Dips: What You Should Know
by Zacks Equity Research
In the latest trading session, Moderna (MRNA) closed at $81.81, marking a +1.98% move from the previous day.
Moleculin Surges on Manufacturing Deal for Coronavirus Therapy
by Zacks Equity Research
Moleculin (MBRX) signs an agreement with Sterling Pharma Solutions for manufacturing and supply of WP1122, which is being developed as potential treatment for COVID-19.
Biotech Stock Roundup: GILD, MRNA Give Coronavirus Treatment Updates & More
by Zacks Equity Research
The biotech sector remains in focus with updates on coronavirus treatments and other pipeline updates.
Travel & Leisure ETFs Jump on Vaccine Optimism
by Sweta Killa
Investors rushed to the beaten-down sectors, including cruise lines, airlines, hotel and casino operators, and travel and entertainment-booking companies.
Stock Market News for Jul 16, 2020
by Zacks Equity Research
Benchmarks edged up on Wednesday as investors cheered promising data for a potential COVID-19 vaccine and few better-than-expected quarterly earnings reports.
The Zacks Analyst Blog Highlights: Moderna, BioNTech, Pfizer, GlaxoSmithKline and Sanofi
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Moderna, BioNTech, Pfizer, GlaxoSmithKline and Sanofi
Coronavirus Vaccine Hopes Buoy Market: 4 Stocks to Tap the Rally
by Nilanjan Banerjee
With the doses of good news aiding the stock market rally, it will be wise for the investors to invest in growth stocks.
Moderna (MRNA) in Focus: Stock Moves 6.9% Higher
by Zacks Equity Research
Moderna (MRNA) saw a big move last session, as its shares jumped nearly 7% on the day, amid huge volumes.
Vaccine Hopes Boost These Sectors & ETFs
by Sanghamitra Saha
Vaccine hopes and some upbeat banking earnings have boosted the risk-on sentiments in Wall Street.
Moderna Inches Closer to Coronavirus Vaccine: ETFs to Shine
by Sweta Jaiswal, FRM
Moderna plans to begin the Phase 3 study of mRNA-1273 this month.
How to Tap Red-Hot Moderna Stock With ETFs
by Sweta Killa
Moderna shares have surged more than 280% so far this year on the positive development of coronavirus vaccine.
Q2 Earnings in Focus
by Zacks Equity Research
Q2 Earnings in Focus
Goldman Boosts Dow with Best Quarter in Years
by Mark Vickery
Goldman simply blew the doors off Q2 expectations, posting $6.26 per share on $13.3 billion in quarterly revenues which compare very favorably with the $3.97 per share and $10.07 billion in the Zacks consensus.
Company News for Jul 15, 2020
by Zacks Equity Research
Companies in the news are: WIT, FRC, FAST, MRNA
Moderna Rallies on Encouraging Coronavirus Vaccine Study Data
by Zacks Equity Research
Moderna's (MRNA) coronavirus vaccine candidate achieves levels of antibodies similar or higher than those typically found in a patient who recovered from COVID-19 naturally.
The Zacks Analyst Blog Highlights: Pfizer, BioNTech, Moderna, Novavax and Johnson & Johnson
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Pfizer, BioNTech, Moderna, Novavax and Johnson & Johnson
Expect Further Rally in Nasdaq-100 ETFs as Moderna Joins
by Sanghamitra Saha
Moderna shares have gained a whopping 283.6% this year due to successful early-stage clinical trials for COVID-19 vaccine, winning a place on the Nasdaq-100 with the company's sheer success.